Výsledky vyhledávání - "Sara Ramaker"

Effects of Long-Term Sertraline Use on Pediatric Growth and Development: The Sertraline Pediatric Registry for The Evaluation of Safety (SPRITES)

Autor: Francesca Kolitsopoulos, Sara Ramaker, Scott N. Compton, Samuel Broderick, John Orazem, Weihang Bao, Yuliya Lokhnygina, Kristina Marschall, Phillip Chappell

Publikováno v: Journal of Child and Adolescent Psychopharmacology. 33:2-13

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::27a67d04d69d75fb7e32067c8215d70a
https://doi.org/10.1089/cap.2022.0048

Zobrazit plný text záznamu

Sertraline Pediatric Registry for the Evaluation of Safety: Design and Clinical Characteristics of Pediatric Patients Prescribed Sertraline

Autor: Phillip B. Chappell, Francesca Kolitsopoulos, John Orazem, Weihang Bao, Yuliya Lokhnygina, Sara Ramaker, Scott N. Compton, Samuel Broderick

Publikováno v: Journal of Child and Adolescent Psychopharmacology. 31:411-420

Objectives: To describe the study design and clinical characteristics of patients in the Sertraline Pediatric RegIstry for The Evaluation of Safety (SPRITES). Methods: SPRITES is an open-label post...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2dbdbe48d4dcfb21f775365598a984c
https://doi.org/10.1089/cap.2020.0170

Zobrazit plný text záznamu

Diagnosis and Treatment Options for Preschoolers with Attention-Deficit/Hyperactivity Disorder

Autor: Phillip B. Chappell, Sara Ramaker, Sharon B. Wigal, Shannon Lubaczewski, Donna Palumbo, Richat Abbas

Publikováno v: J Child Adolesc Psychopharmacol

Objective: The Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5), classifies attention-deficit/hyperactivity disorder (ADHD) as a neurodevelopmental disorder, with symptoms becoming apparent as early as the preschool years.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbfc124a37b54172be406b9d45e24734
https://europepmc.org/articles/PMC7047251/

Zobrazit plný text záznamu

Safety, Tolerability, and Efficacy of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder: Results from Two Open-Label Extension Trials

Autor: Gina Buckley, Sarah Ruta Jones, Sara Ramaker, Richard D. England, Louise Thurman, Dalia B. Wajsbrot, Sarah Atkinson

Publikováno v: CNS Spectrums. 24:496-506

ObjectiveTwo similarly designed extension studies evaluated the long-term safety and tolerability of desvenlafaxine for the treatment of children and adolescents with major depressive disorder (MDD). Efficacy was evaluated as a secondary objective.Me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf0727f752080ca802895f68e3d935f5
https://doi.org/10.1017/s1092852918001128

Zobrazit plný text záznamu

Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder

Autor: Robert L. Findling, Sarah Atkinson, Sara Ramaker, Richat Abbas, Dalia B. Wajsbrot, Shannon Lubaczewski, Richard D. England

Publikováno v: Journal of Child and Adolescent Psychopharmacology

Objective: To evaluate the short-term efficacy and safety of desvenlafaxine versus placebo in the treatment of children and adolescents with major depressive disorder (MDD). Methods: Outpatient children (7–11 years) and adolescents (12–17 years)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65d66cacb0ac2792923f5d7618a0e661
https://doi.org/10.1089/cap.2017.0099

Zobrazit plný text záznamu

Pharmacokinetics and Tolerability of Single-Ascending Doses of Desvenlafaxine Administered to Children and Adolescents with Major Depressive Disorder

Autor: Alice I. Nichols, Lingfeng Yang, Karen A. Tourian, Robert L. Findling, Sara Ramaker, James Groark, Deborah Chiles

Publikováno v: Journal of Child and Adolescent Psychopharmacology. 26:909-921

To investigate the safety and pharmacokinetic profile of ascending doses of desvenlafaxine in children and adolescents with major depressive disorder. Assessment of the effect of desvenlafaxine on depression symptoms was exploratory.The 8-week, open-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d62ad92e2dfd2ff046ffb84976c8cf01
https://doi.org/10.1089/cap.2016.0009

Zobrazit plný text záznamu

Re: 'Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder: Design, Definitions, and Ongoing Challenges for Child and Adolescent Psychopharmacology Research' by Strawn JR and Croarkin PE (J Child Adolesc Psychopharmacol 2018;28:(5)363)

Autor: Phil Chappell, Deborah Chiles, Dalia B. Wajsbrot, Sara Ramaker, Karen L. Weihs

Publikováno v: Journal of Child and Adolescent Psychopharmacology. 29:245-246

Objective: The purpose of this study was to assess the effect of guanfacine extended release (GXR) adjunctive to a psychostimulant on oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder (ADHD).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bdf3b6020714037510abe6ea4f598b5
https://doi.org/10.1089/cap.2018.0163

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Safety and Tolerability of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder

Autor: James Groark, Lingfeng Yang, Robert L. Findling, Deborah Chiles, Sara Ramaker, Karen A. Tourian

The purpose of this study was to assess long-term safety and tolerability of desvenlafaxine (administered as desvenlafaxine succinate) in children and adolescents with major depressive disorder (MDD).An 8 week, multicenter, open-label, fixed-dose stu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4b5ee76416c71a0b448189418d3c131
https://europepmc.org/articles/PMC4026302/

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání